High-Dose Oral CBD Produced Surprisingly Low Blood Levels With a 2-5 Day Elimination Half-Life | Research

The takeaway

Despite receiving approximately 700 mg/day of oral CBD, Huntington's Disease patients achieved mean plasma levels of only 5.9 to 11.2 ng/mL, with CBD clearing from the body over 2-5 days after discontinuation.

Read this if you take CBD products and want to understand how much actually reaches your bloodstream after oral dosing.

700 mg/day oral CBD produced only 5.9-11.2 ng/mL in plasma

What the researchers found

Researchers developed and validated a method to measure CBD in blood plasma, then used it to track CBD levels in 14 Huntington's Disease patients receiving high-dose oral CBD (10 mg/kg/day, approximately 700 mg/day) for six weeks.

Despite the high oral dose, mean plasma CBD levels ranged from only 5.9 to 11.2 ng/mL across the six weeks. This represented poor oral bioavailability, meaning most of the ingested CBD was not reaching the bloodstream.

One week after stopping CBD, plasma levels averaged 1.5 ng/mL and were virtually undetectable thereafter. The elimination half-life was estimated at 2 to 5 days. There were no gender differences in either CBD levels or elimination half-life.

Importantly, no delta-1-THC (the major psychoactive cannabinoid) was detected in any patient's blood, confirming CBD did not convert to THC in the human body at this dose.

Why it matters

This study revealed a critical pharmacological challenge for oral CBD: very low bioavailability. Patients taking 700 mg/day achieved plasma levels well below concentrations shown to be active in laboratory studies. This has major implications for CBD dosing and product formulation.

The numbers in context

Fourteen patients. CBD dose: 10 mg/kg/day (approximately 700 mg/day). Plasma levels: 5.9-11.2 ng/mL over 6 weeks. One week post-cessation: 1.5 ng/mL. Elimination half-life: 2-5 days. Assay sensitivity: 500 pg/mL. No gender differences.

How the study worked

Pharmacokinetic study within a double-blind crossover trial. Plasma CBD levels were measured weekly using trimethylsilyl derivatization, capillary gas chromatography, and ion trap mass spectrometry in positive ion chemical ionization mode. Assay sensitivity: approximately 500 pg/mL. Precision: approximately 10-15%.

What this study cannot tell us

Fourteen patients is a small pharmacokinetic sample. Patients had Huntington's Disease, which could affect drug metabolism. Only oral CBD was tested; other routes of administration would produce different pharmacokinetic profiles.

How to read the evidence

A pharmacokinetic study embedded within a controlled clinical trial. Rigorous analytical methods but small sample size.

When this study was published

Published in 1991. CBD formulation science has advanced substantially, with modern products achieving better bioavailability.

The bigger picture

The bioavailability problem identified here remains one of the central challenges of oral CBD therapeutics. Modern CBD formulations (lipid-based, nanoemulsions) attempt to address exactly this issue. The finding that CBD does not convert to THC in humans was also important for regulatory and safety discussions.

Questions still open

Would different formulations dramatically improve CBD bioavailability? Do the low plasma levels explain the lack of efficacy in the companion clinical trial? What plasma CBD concentration is needed for therapeutic effects in different conditions?

Common questions

How much CBD actually gets into the blood?

In this study, 700 mg/day of oral CBD produced mean plasma levels of only 5.9-11.2 ng/mL, indicating very low oral bioavailability.

Does CBD convert to THC in the body?

No. Despite high doses over six weeks, no THC was detected in any patient's blood, confirming CBD does not convert to the psychoactive compound in the human body.

Read the original research

Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans.

Pharmacology, biochemistry, and behavior, 40(3), 517-22

View on PubMed ↗

Citation

Consroe, P; Kennedy, K; Schram, K. (1991). Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans.. Pharmacology, biochemistry, and behavior, 40(3), 517-22.